Key Points:
• A Cambridge-led trial found that adding low-dose megestrol to standard hormone therapy slows tumor growth in ER-positive breast cancer.
• Megestrol also helps ease hot flashes from anti-estrogen treatment, potentially improving therapy adherence.
• Benefits appeared at both low and higher doses, supporting use with fewer side effects.
A new study suggests a common treatment for menopause hot flashes may also slow the growth of certain breast cancers. Researchers in the United Kingdom tested the addition of megestrol acetate—a synthetic progesterone—to conventional anti-estrogen therapy with letrozole in post-menopausal women. Results indicate a stronger anti-cancer effect when megestrol is included.
Most breast cancers in women are estrogen receptor-positive (ER-positive), meaning tumor cells rely on estrogen to grow. Letrozole, an aromatase inhibitor, blocks estrogen production and forms a key part of adjuvant treatment to prevent recurrence after surgery. However, it commonly causes menopausal side effects like hot flashes, joint pain and bone density loss.
These side effects can make long-term adherence difficult for many patients. Clinicians often prescribe megestrol to reduce vasomotor symptoms. The drug mimics progesterone, helping relieve hot flashes while potentially supporting ongoing hormone therapy.
The PIONEER trial tested this dual benefit in a pre-surgical “window of opportunity” design. Researchers enrolled nearly 200 women with early-stage ER-positive breast cancer. Participants received standard letrozole alone or letrozole with either 40 mg or 160 mg of megestrol daily for two weeks before surgery.
Tumor samples taken before and after the treatment period showed that combining megestrol with letrozole further reduced cell proliferation compared with letrozole alone. Notably, the lower and higher doses produced similar effects, suggesting effective anti-proliferative action even at reduced dose levels.
Researchers believe two mechanisms may underlie these findings. First, megestrol’s relief of hot flashes may improve patients’ ability to stick with hormone therapy, indirectly benefiting outcomes. Second, megestrol itself appears to directly limit tumor cell growth by altering estrogen receptor activity and genomic binding in the cancer cells.
Importantly, using a lower dose may help strike a balance between efficacy and side effects. High doses of megestrol can cause weight gain, hypertension and other complications. However, the study found that even the 40 mg dose delivered measurable anti-cancer activity, opening the door for potentially better tolerability in long-term use.
While these results are promising, investigators caution that further research is essential. The PIONEER trial lasted only two weeks, limiting assessment of long-term safety and sustained cancer control. Larger, longer trials would be needed to confirm whether megestrol consistently improves outcomes when added to standard endocrine therapy.
Researchers call for phase III trials that track invasive disease-free survival and other clinical endpoints. Such studies would help determine if the combination can be recommended in routine practice. For now, the early evidence hints at a dual role for megestrol in supporting both quality of life and tumor suppression among women on anti-estrogen therapy.
If confirmed in larger studies, this approach could benefit thousands of patients worldwide. By reducing debilitating menopausal symptoms and possibly slowing tumor growth, low-dose megestrol added to letrozole may offer a more tolerable and effective long-term treatment path for people with ER-positive breast cancer.
